TY - JOUR KW - Computer Simulation KW - Drug Design KW - Humans KW - Ligands KW - Nuclear Proteins KW - Small Molecule Libraries KW - CREB-Binding Protein KW - Transcription Factors KW - Protein Domains AU - D. Spiliotopoulos AU - A. Caflisch AB -
We review the results of fragment-based high-throughput docking to the N-terminal bromodomain of BRD4 and the CREBBP bromodomain. In both docking campaigns the ALTA (anchor-based library tailoring) procedure was used to reduce the size of the initial library by selecting for flexible docking only the molecules that contain a fragment with favorable predicted binding energy. Ranking by a force field-based energy with solvation has resulted in small-molecule hits with low-micromolar affinity and favorable ligand efficiency. Importantly, the binding modes predicted by docking have been validated by X-ray crystallography. One of the hits for the CREBBP bromodomain has been optimized by medicinal chemistry into a series of potent and selective ligands.
BT - Drug Discovery Today. Technologies C1 - 0212 DA - 2016 Mar DO - 10.1016/j.ddtec.2016.06.003 J2 - Drug Discov. Today Technol. LA - eng M3 - Research Article N2 -We review the results of fragment-based high-throughput docking to the N-terminal bromodomain of BRD4 and the CREBBP bromodomain. In both docking campaigns the ALTA (anchor-based library tailoring) procedure was used to reduce the size of the initial library by selecting for flexible docking only the molecules that contain a fragment with favorable predicted binding energy. Ranking by a force field-based energy with solvation has resulted in small-molecule hits with low-micromolar affinity and favorable ligand efficiency. Importantly, the binding modes predicted by docking have been validated by X-ray crystallography. One of the hits for the CREBBP bromodomain has been optimized by medicinal chemistry into a series of potent and selective ligands.
PY - 2016 SE - 81 SP - 81 EP - 90 T2 - Drug Discovery Today. Technologies TI - Fragment-based in silico screening of bromodomain ligands VL - 19 SN - 1740-6749 ER -